Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$5.24 – $9.41
100% from low
Exchange
OTC Link
ADRC
Borrow rate
15.02%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $42.60B | $38.87B | $38.65B | $37.77B | $38.61B | $40.71B | $44.71B | $43.36B |
| Cost of revenue | $20.99B | $19.17B | $19.31B | $19.98B | $20.30B | $22.30B | $25.29B | $24.23B |
| Gross profit | $21.61B | $19.70B | $19.33B | $17.79B | $18.31B | $18.41B | $19.42B | $19.13B |
| Gross margin | 50.7% | 50.7% | 50.0% | 47.1% | 47.4% | 45.2% | 43.4% | 44.1% |
| R&D | $3.0M | $211.0M | $195.0M | $260.0M | $433.0M | $214.0M | $162.0M | $0 |
| Operating income | $9.24B | $4.81B | $7.06B | $7.07B | $8.67B | $7.82B | $7.00B | $1.44B |
| EBITDA | $9.82B | $5.54B | $7.27B | $8.67B | $9.93B | $10.19B | $9.90B | $2.16B |
| Net income | $6.01B | $6.46B | $4.66B | $4.81B | $6.49B | $5.23B | $4.40B | −$1.08B |
| Net margin | 14.1% | 16.6% | 12.1% | 12.7% | 16.8% | 12.8% | 9.9% | -2.5% |
| EPS (diluted) | 13.17 | 14.16 | 10.64 | 10.53 | 14.32 | 11.77 | 9.91 | -2.44 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $37.3B | $12.47 | $11.90–$13.24 | 1 |
| 2028 | $41.4B | $13.67 | $13.04–$14.51 | 1 |
Forward consensus · source: Financial Modeling Prep
ASPEN PHARMACRE HL UN/ADR
No one on the platform currently holds APNHY.
No tracked institution reports a position in APNHY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-10-03 | $0.1219 | 2025-10-21 |
| 2024-09-20 | $0.2070 | 2024-10-08 |
| 2023-09-21 | $0.1795 | 2023-10-11 |
| Execution date | Ratio |
|---|---|
| 2012-07-18 | 5-for-1 |
No one on the platform has traded APNHY yet.
| +0.00% |
| $2.6B |
| — |
| HAWPYHaw Par Corporation Limited | $53.50 | +0.00% | $3.0B | — |
| HMDCFHUTCHMED (China) Limited | $2.16 | +0.00% | $1.9B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.4× earnings vs its 0.8× historical median P/E.
Fair value ≈ $18.97 · price $9.41 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.